Tumor necrosis factor (TNFa) has been invoked as an adipostat. Accordingly, the adipose tissue expression of TNFa has been shown to be proportional to the degree of adiposity. The regulatory role of TNFa in obesity may be controlled by several mechanisms. These include the inhibitory effect on LPL activity, the mediation on glucose homeostasis or the effect on leptin. To assess the role of TNFa in obesity we measured adipocyte TNFa expression in 96 females with a wide range of adiposity and with or without type 2 diabetes. We analysed the relationship between TNFa expression, adipocyte LPL activity, insulin resistance and leptin in this population. RESULTS: The TNFa and leptin expression of the adipose tissue in obese and morbid obese patients were significantly higher than in controls. Obese and morbid obese patients had slightly higher levels of LPL activity, but these differences were not significant. We observed a significant relationship between adipose TNFa expression and body mass index (r ¼ 0.35, P < 0.001). TNFa expression was negatively related to LPL activity (r ¼ 7 0.28, P < 0.05) and positively related to leptin expression (r ¼ 0.35, P < 0.001). CONCLUSION: Our results indicate that obese women, even those with morbid obesity, over-express TNFa in subcutaneous adipose tissue in proportion to the magnitude of the fat depot and independently of the presence of type 2 diabetes. The TNFa system may be a homeostatic mechanism that prevents further fat deposition by regulating LPL activity and leptin production.
Introduction
Obesity is a chronic condition of complex aetiology that is highly prevalent in affluent Western societies. In recent years, it has been suggested that tumour necrosis factor (TNFa) is an important regulating factor of this condition. 1, 2 Evidence from animals suggests that TNFa exerts a central effect on the regulation of body weight, either by decreasing energy intake or by inducing thermogenesis. 3 -5 Several authors have suggested that TNFa produced in the adipocyte acts as a true adipostat, 2, 6, 7 but no direct evidence has yet been provided to support this. Some of the peripheral effects of TNFa are the inhibition of LPL activity, 8 -10 the downregulation of the expression of the glucose transporter GLUT 4, 11 the inhibition of insulin receptor activity 12, 13 and the induction of adipose leptin production.
14 All these effects have been described in humans, culture cells and animals. Therefore, either by direct action on LPL activity or by favouring a state of insulin resistance, TNFa produced by adipocyte may be a mechanism that helps to limit obesity.
In obese humans, overexpression of TNFa in adipose tissue is proportional to the extent of the fat depot. This supports the notion that TNFa is an adipostat. 15 -17 However, Kern et al observed that TNFa expression decreases in extre-mely obese non-diabetic subjects, which suggests that a lower production of TNFa in adipocyte is involved in the maintenance and progression of obesity in these subjects. 15 The main aim of this study was therefore to evaluate the levels of TNFa expression in the adipose tissue of a large sample of women whose degrees of adiposity were considerably different. We also analysed the relationship between this cytokine and adipocyte LPL activity, insulin resistance and leptin in this population.
Methods
Subjects and sample acquisition A group of 96 females aged between 18 and 65 and with a wide range of adiposity (body mass index (BMI) 20 -64 kg=m 2 ) were recruited in the Sant Joan University Hospital in Reus, Spain. The subjects were defined as obese if their BMI was between 27 and 40 kg=m 2 (n ¼ 54) and as morbid obese if their BMI was above 40 kg=m 2 (n ¼ 27). This is in accordance with the Spanish consensus for the diagnosis of obesity. 18 Patients were classified as having type 2 diabetes if a previous diagnosis had been performed or if fasting plasma glucose was > 7 mmol=l on two consecutive occasions. 19 The control group consisted of healthy females with a BMI between 20 and 27 kg=m 2 (n ¼ 15). For two days before the study, all subjects were placed on an isocaloric diet calculated on the basis of individual requirements. The diet was made up of 50% carbohydrate, 20% protein and 30% fat. Blood samples were taken in fasting conditions at 8:00 and 10:00 am. Plasma was separated immediately by centrifugation and aliquots were frozen at 7 80 C for subsequent analysis. Adipose tissue samples were obtained from subcutaneous abdominal depots during abdominal elective surgical procedures (bariatric surgery, cholecistectomy and surgery of abdominal hernia). In 36 patients, adipose tissue samples were obtained by an incisional biopsy also performed in the abdominal wall. The anaesthetic procedures were standardised either in elective surgery or in biopsy procedures. In biopsy procedures, 1% mepivacaine was used. Epinephrine was avoided. Samples of adipose tissue were quickly minced, frozen in liquid nitrogen and stored at 7 80 C for further analysis. As a large enough sample of adipose tissue could not be obtained from all the females, we prioritised the measurements of leptin and TNFa expression. These measurements were taken in 83 and 78 subjects, respectively. Adipose tissue LPL activity measurements were only available in 72 subjects.
All subjects were free of inflammatory or infectious diseases and none were receiving anti-obesity or anti-inflammatory drugs at the time of the study. Patients were excluded if they had neoplastic, renal, hepatic or active systemic diseases, hypothyroidism or endocrine diseases other than diabetes, or if they had been on a restrictive diet during the week before the study. All patients reported that their weight had been stable during the previous 3 months. None of the diabetic patients were being treated with insulin. The study protocol was accepted by the hospital ethics committee and all subjects gave their written informed consent to participate.
Body composition analysis
Weight and height were determined in all subjects, and the BMI was then calculated. Waist circumference was measured midway between the lower rib margin and the iliac crest. Hip circumference was determined as the widest circumference measured on the great trochanter. The waist-to-hip ratio (WHR) was then calculated. Whole body impedance at 50 kHz was measured as previously described 20 using a tetrapolar bioelectrical impedanciometer (Human-Im-Scan Dietosystem, Spain). Fat-free mass (FFM) was estimated using the gender-specific equations validated by Segal. 21 Fat mass was estimated by the difference between body weight and FFM.
Resting energy expenditure (REE) measurements Energy expenditure measurements were determined in fasting conditions by 30 min open-circuit indirect calorimetry (Deltatrac 1 , Datex Instrumentation, Helsinki, Finland), as previously described. 22 The within-individual coefficient of variation for day-to-day replicate measurements of REE was 2.3%. REE was calculated using Weir's equation 23 and the results are expressed as kJ=day. REE was adjusted by FFM (REE FFM ) using the general linear model procedure. The fasting respiratory quotient (RQ) was calculated as VCO 2 =VO 2 .
Plasma biochemical analysis
Fasting plasma glucose, glycosylated haemoglobin and lipid profile (triglycerides, total cholesterol, and high-, low-and very low-density lipoprotein cholesterol) were measured enzymatically by the hospital's routine chemistry laboratory. Fasting plasma insulin was determined by a commercial radioimmunoassay kit (Amersham, Little Chalfont, UK). The intra-and inter-assay coefficients of variation were 5.05 and 13.4%, respectively and the lowest limit of detection was 48 pg=ml. The homeostasis model assessment of insulin resistance (HOMA IR) was calculated as previously described. 24 Plasma TNFa concentrations were measured by enzymelinked immunoabsorbent assay (Pharmingen, San Diego, CA, USA). The intra-and inter-assay coefficients of variation were < 5.8 and < 13.8%, respectively. Because sTNFR levels are easily detectable in plasma and appear to act as a buffer system prolonging the biological effects of TNFa, 25, 26 plasma concentrations of soluble TNFa receptors (sTNFR1 and sTNFR2) were determined by immunoenzymometric assay (BioSource, Fleunes, Belgium). The minimum detectable concentrations were 50 pg=ml and 0.1 ng=ml, respectively.
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Plasma leptin levels were measured by radioimmunoassay using a commercial kit (Linco Research, St Louis, MO, USA). Within-and between-assay variations were 4.98 and 4.5%, respectively. The limit of sensitivity was 0.5 ng=ml.
RNA extraction and measurements of TNFa and leptin mRNA levels Total RNA from 150 -250 mg of subcutaneous adipose tissue was extracted with a TriPure Isolation Reagent (Boheringer Manheim GmbH, Ottweiler, Germany) using the method developed by Chomczynski and Sacchi. 27 RNA quality was verified by electrophoresis in a 1.5% agarose gel containing ethidium bromide and the RNA concentration was quantified by spectrophotometry. To measure TNFa and leptin expression, quantitative competitive PCR assays were developed. First strand cDNA was synthesised from 0.5 mg of total RNA using random hexamers in the presence of ditiothreitol and RNAse inhibitors. Specific primers of leptin 28 (GenBank D63710), TNFa 29 (GenBank X02910) and human beta-actin 30 (GenBank M10277) were derived from the gene sequences published in GeneBank. PCR reactions were performed in a thermocycler (Progene Techne, Cambridge). In a tube reaction we amplified TNFa and beta-actin by 33 cycles at 65 C, and in another reaction we amplified leptin and beta-actin by 30 cycles at 45 C. The resulting ethidium bromide-stained gel was imaged using the Kodac Digital Science software (Kodac, Science Park, New Haven, CT, USA). To exclude possible variations in mRNA yield among samples, TNFa and leptin mRNA levels were expressed as specific mRNA divided by beta-actin mRNA.
Adipose tissue LPL activity LPL activity was measured in an extract of adipose tissue, as previously described by Ramirez et al 31 using [
3 H]trioleincontaining substrate emulsified with oleat, and containing normal human serum as a source of ApoC-II. Samples were incubated with the substrate solution containing heparin for 30 min at 25 C and 3 H-labelled free fatty acids were separated by centrifugation. This activity was standarised to units of DNA, and DNA levels were determined in the same tissue homogenates by fluorimetric assay using Hoechst 33342 (IMATRA SA, Barcelona, Spain).
Statistical analysis
Statistical analysis was performed using the SPSS=PC package. Descriptive results are expressed as means and standard error (s.e.). Differences in mean values between groups were assessed by one-way analysis of variance. Post-hoc comparisions were carried out with the less significant differences test. The contingency table chi-square test was used to analyse qualitative traits. The relationship between variables was analysed by the Pearson correlation coefficient test. A step-wise multiple regression analysis was performed to identify the independent predictors of TNFa expression, with BMI, percentage body fat, fasting insulin, HOMA IR and the presence of diabetes as independent variables. In another model, LPL activity was introduced as the dependent variable and BMI, percentage body fat, TNFa expression and the presence of diabetes were introduced as independent variables. Covariance analysis was used to adjust variables, and the significance of the differences between groups was assessed by the F-statistic. Significance was set at P < 0.05.
Results
The biometric characteristics of subjects are described in Table 1 . There were no differences in age and height between groups. In the biochemical analysis (Table 2) , there were no significant differences in fasting glucose levels, plasma total cholesterol, HDL cholesterol and LDL cholesterol among the groups. Plasma VLDL cholesterol and triglycerides were higher in obese and morbid obese patients. There were no significant differences in fasting RQ or adjusted REE between groups (Table 1) .
Twenty-four patients were found to be type 2 diabetics. Sixteen of these were in the obese group (29.6%) and eight Adipocyte TNFa expression and LPL activity M Bulló et al were in the morbid obese group (29.6%). There were no significant differences in age, anthropometric characteristics, plasma total cholesterol, HDL cholesterol or LDL cholesterol in obese patients with type 2 diabetes. Fasting insulin and HOMA IR were higher in obese and morbid obese patients (Table 2 ). Morbid obese patients had a greater resistance to insulin than obese patients. Leptin levels and both sTNFR forms were significantly higher in obese patients than in controls. They were also higher in morbid patients than in obese patients (Table 2) . On the other hand, there were no differences in plasma TNFa levels between groups (data not shown). Both sTNFR1 and sTNFR2 plasma concentrations were slightly higher in patients with type 2 diabetes than in patients without it (2.02 AE 0.11, 1.69 AE 0.73 ng=ml, P ¼ 0.019, by sTNFR1; 4.84 AE 0.30, 4.32 AE 0.16 ng=ml, P ¼ 0.112, by sTNFR2), although the difference did not reach statistical significance for sTNFR2. Plasma leptin levels were related to both sTNFR1 and sTNFR2 (r ¼ 0.38, P < 0.001 in both cases). In adipose tissue, both obese and morbid obese patients had significantly higher TNFa and leptin expression than controls ( Figure 1 ). Morbid obese patients had a higher TNFa adipose tissue expression than obese subjects, but the difference was not significant. No significant differences were observed in LPL activity between groups, although obese and morbid obese patients had slightly higher mean values than controls (20.3 AE 2.5 mU=ng DNA in the obese group, 25.6 AE 3.3 mU=ng DNA in the morbid obese group and 14.5 AE 3.1 mU=ng DNA in the control group; Table 3 ). After we had adjusted for differences in adiposity, TNFa expression was higher in the group in which type 2 diabetes was present (Table 3 ). There were no significant differences in LPL activity between the diabetic and the non-diabetic groups (25.1 AE 3.8 vs 20.9 AE 2.4 mU=ng DNA) when differences in fat mass were taken into account.
Adipose tissue TNFa expression was positively related to BMI (r ¼ 0.35; P < 0.005), percentage body fat (r ¼ 0.35; P < 0.005), leptin expression (r ¼ 0.37, P < 0.005), sTNFR1 (r ¼ 0.33, P < 0.005) and sTNFR2 (r ¼ 0.30, P < 0.01). LPL adipose tissue activity was negatively related to TNFa expression (r ¼ 7 0.28, P < 0.05; Figure 2 ) and positively related to BMI (r ¼ 0.23, P ¼ 0.05). Both sTNFR were also related to fasting insulin (r ¼ 0.28 and r ¼ 0.31, P < 0.005) and HOMA IR (r ¼ 0.32 and r ¼ 0.36, P < 0.005).
In a multiple linear-regression analysis, BMI was an independent predictor of TNFa expression, which explained 13% of its variability (P ¼ 0.001). TNFa adipose tissue expression and BMI were the only significant predictors of adipose tissue LPL activity (r 2 ¼ 0.16, P ¼ 0.006). Fifty percent of diabetic patients were not under good glycaemic control according to ADA recommendations (HbA1c ! 7%). 19 When we compared poorly controlled diabetic patients to well-controlled diabetic patients, we found no significant differences in TNFa or leptin adipose tissue expression, plasma levels of sTNFRs or LPL activity (data not shown).
Discussion
We studied a large sample of women with a wide range of adiposity in homogeneous and carefully controlled energetic metabolic conditions. Our data indicate that the adipocytes of obese patients, including those with morbid obesity, overexpressed TNFa in proportion to the degree of adiposity. In fact, of the variables considered (BMI, percentage body fat, fasting insulin, HOMA IR and the presence of diabetes), BMI was the main predictor of adipocyte TNFa expression throughout the population.
Our results confirm and extend the findings of Hotamisligil et al in a small sample of 19 obese females. 16 These authors reported that the adipose-tissue expression of TNFa was positively related to BMI and decreased in proportion to the loss in body weight. This suggests that TNFa has an important role in the pathophysiology of obesity. Kern et al observed a significant positive relationship between TNFa expression in fat tissue and indices of adiposity when severely obese patients were excluded from the analysis. 15 They also reported lower TNFa mRNA levels in very obese subjects. These authors suggest that morbid obese patients are more likely to develop obesity because the adipose tissue restricts cytokine production. Our observation that morbid patients also overexpressed TNFa in fat cells differs from the findings of Kern et al in 1995. The heterogeneity of Kern's study sample, which included patients of both sexes and excluded type 2 diabetic subjects, may partly explain this discrepancy. In a recent study in non-diabetic subjects, Koistinen et al reported that the adipose TNFa expression of morbid obese males was four times higher than that of lean or obese males. 17 However, this overexpression was not demonstrated in obese or morbid obese females in the same study. Our study worked with the largest sample of females to date, and showed that morbid obese females presented a higher expression of TNFa in adipose tissue, regardless of the presence or absence of type 2 diabetes.
It has been suggested that adipose TNFa production is a counter-regulatory mechanism that acts in various ways to prevent further body-fat deposition. Some authors have suggested that TNFa is an inductor of insulin resistance in experimental models. 12, 13, 32 However, the role of adipose tissue TNFa in human insulin resistance is controversial. 
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Two studies have demonstrated that the expression of adipose tissue TNFa is not related to whole-body insulin sensitivity, either in non-diabetic obese 17 or lean subjects. 33 Furthermore, the administration of an anti-TNFa antibody failed to increase sensitivity to insulin in a group of type 2 diabetic patients. 34 On the other hand, a positive relationship between TNFa mRNA expression in adipose tissue and the level of hyperinsulinaemia has been reported both in Figure 1 Levels of adipose tissue leptin and TNFa expression (panels A and B, respectively) and adipose tissue LPL activity (panel C) in relation to the degree of adiposity. Values are expressed as means (s.e.). *P < 0.05, **P < 0.001 vs control group.
Adipocyte TNFa expression and LPL activity M Bulló et al females 16 and in non-diabetic males. 17 Our results support the theoretical inductive role of adipose tissue TNFa in obesity-related insulin resistance. Firstly, the circulating concentrations of soluble TNFRa were positively related to plasma insulin levels and HOMA (an index of insulin resistance) and sTNFR1 levels were higher in patients with type 2 diabetes. Secondly, the adipose tissue expression of TNFa was slightly higher, though not significantly so, in diabetic patients than in non-diabetic patients.
One of the mechanisms by which insulin resistance can limit the increase in adiposity is by modulating LPL activity. In agreement with Kern et al, 15 adipose tissue LPL activity was negatively related to adipocyte TNFa expression. In fact, in our study both the expression of this cytokine and the BMI were the only significant predictors of LPL activity. This finding supports the notion that, in accordance with in vitro evidence, 8, 10 this cytokine has an inhibitory effect on LPL in vivo. Moreover, the effect of this cytokine on this enzymatic activity seems to be independent of the action of insulin since there seems to be no relationship between LPL activity and plasma insulin or HOMA IR as a parameter reflecting insulin resistance. Moreover, the levels of LPL activity were not significantly different between diabetic and non-diabetic patients. Other authors 35 -37 previously suggested that LPL activity is modulated regardless of insulin, probably by TNFa. This may be due to the induction of nitric oxide synthase 37 and the fact that NF-Y and octamer-binding protein (OCT-1) cease to interact with LPL DNA. 39 TNFa may also be involved in regulating fat stores through leptin, which has been shown to play a central role in regulating energy balance. TNFa directly affects leptin production in adipocyte-cultured cells, 40 and transient increases in serum leptin have been observed after TNFa has been administered in humans.
14 However, controversial in vitro data argue against the stimulatory effect of TNFa on adipocyte leptin production. 41, 42 In our study, we observed a positive relationship between the expression of these two proteins in adipose tissue. In addition, we found a positive relationship between plasma leptin and soluble TNFR levels. Whether these relationships are due to the direct action of TNFa on leptin production or to other mechanisms cannot be answered from this study. To our knowledge, only two studies have analysed the relationship between the expression of these two proteins in human fat tissue: these studies describe either a positive 43 or a nonexistent 17 association in very small samples of obese patients.
In conclusion, obese women overexpress TNFa in subcutaneous adipose tissue even at the extreme range of adiposity, and this overexpression does not depend on the presence of type 2 diabetes. The relationship between TNFa expression, leptin production and adipose tissue LPL activity is in agreement with the hypothesis that the TNFa-system is a homeostatic mechanism that aims to limit fat depot enlargement. Further research is needed to confirm the role of TNFa in obesity.
